Selinexor affects the platelet counts of patients with solid tumors in a dose-dependent manner. (A) Absolute platelet count as a function of platelet count at baseline for patients treated with 7 to 8 high doses of selinexor (>100 mg) in the first 28-day cycle (N = 28). (B) Absolute platelet count as a function of platelet count at baseline for patients treated with 7 to 8 low doses of selinexor (50-70 mg) in the first 28-day cycle (N = 36). Each point represents the platelet count of an individual patient. The regression lines were derived from the average platelet count loss from baseline (slope values 0.24 and 0.53, R² = 0.31 and R² = 0.71, respectively). (C) Average (±SD) change in platelet count as function of time for patients treated with 7 to 8 doses of selinexor (30-145 mg) per 28-day cycle. The number of patients for each time point is listed on the graph.